248 related articles for article (PubMed ID: 33328343)
21. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
22. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effects of anti-angiogenesis and immune checkpoint blockade - a new era of systemic chemotherapy for hepatocellular carcinoma.
Eso Y; Seno H
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):493-495. PubMed ID: 33906802
[No Abstract] [Full Text] [Related]
24. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
[TBL] [Abstract][Full Text] [Related]
25. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
28. [The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Noda T; Nagano H; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Ohsuga K; Kim T; Tomoda K; Nakamura H; Monden M
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1221-5. PubMed ID: 16969014
[TBL] [Abstract][Full Text] [Related]
29. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
30. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".
Li X; Liang P; Ye X
J Cancer Res Ther; 2019; 15(2):267-268. PubMed ID: 30964095
[No Abstract] [Full Text] [Related]
31. Systemic therapy for advanced hepatocellular carcinoma: a review.
Nowak AK; Chow PK; Findlay M
Eur J Cancer; 2004 Jul; 40(10):1474-84. PubMed ID: 15196530
[TBL] [Abstract][Full Text] [Related]
32. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S; Li Q; Gu S; Chen X; Lin L; Wang Z; Xu A; Chen X; Zhou C; Ren Z; Yang L; Xu L; Bai Y; Chen L; Li J; Pan H; Cao B; Fang W; Wu W; Wang G; Cheng Y; Yu Z; Zhu X; Jiang D; Lu Y; Wang H; Xu J; Bai L; Liu Y; Lin H; Wu C; Zhang Y; Yan P; Jin C; Zou J
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):559-568. PubMed ID: 33971141
[TBL] [Abstract][Full Text] [Related]
33. Combination of Anti-Programmed Death 1 Therapy and Apatinib for a Patient with Hepatocellular Carcinoma and Brain Metastasis: Case Report and Literature Review.
Liu Y; Hao S; Ji N; Wang J; Zhang L
World Neurosurg; 2020 Nov; 143():114-117. PubMed ID: 32534262
[TBL] [Abstract][Full Text] [Related]
34. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
[TBL] [Abstract][Full Text] [Related]
36. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
38. Are there indications for chemotherapy in hepatocellular carcinoma?
Johnson PJ
Surg Oncol Clin N Am; 2003 Jan; 12(1):127-34. PubMed ID: 12735134
[TBL] [Abstract][Full Text] [Related]
39. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
40. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]